title: The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.
abstract: OBJECTIVE
  This study aimed to investigate the methylation status of EGF-like and two follistatin-like domains 2 (TMEFF2) promoter and its correlation with tumor stage and survival outcome in renal cell carcinoma (RCC).
  
  
  METHODS
  Paraffin-embedded specimens from 42 RCC patients were analyzed for TMEFF2 methylation by methylation-specific polymerase chain reaction. The distribution of TNM/AJCC stages and survival time were compared among patients with unmethylated and methylated TMEFF2.
  
  
  RESULTS
  There were 25 (59.5%) and 17 (40.5%) cases with methylated (M group) and unmethylated (M group) TMEFF2, respectively. There were more early-stage cancer patients in U group than in M group. Kaplan-Meier survival analysis showed that U group had a better but not significant survival outcome than M group (P = 0.123).
  
  
  CONCLUSIONS
  These findings showed that TMEFF2 methylation is not rare in RCC, and methylation may play an important role in the tumorigenesis of ccRCC.
authors.affiliation: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.|Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Enjing
authors.initials: E
authors.lastname: Chen
authors.affiliation: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Fufu
authors.initials: F
authors.lastname: Zheng
authors.affiliation: Department of Urology, Jiangmen Central Hospital, Jiangmen, Guangdong 529030, China.|Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Xiaoxu
authors.initials: X
authors.lastname: Yuan
authors.affiliation: Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
authors.forename: Yunlin
authors.initials: Y
authors.lastname: Ye
authors.affiliation: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Yuping
authors.initials: Y
authors.lastname: Dai
authors.affiliation: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
authors.forename: Lingwu
authors.initials: L
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics*; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000401:mortality* / Q000473:pathology; D019175:DNA Methylation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D009367:Neoplasm Staging; D011401:Promoter Regions, Genetic; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D008565:Membrane Proteins; D009363:Neoplasm Proteins; C423567:TMEFF2 protein, human
keywords: Renal cell carcinoma; TMEFF2; promoter methylation